The net chance of a longer survival as a patient-oriented measure of treatment benefit in randomized clinical trials

JAMA Oncology

Volumn 2, Issue 7, 2016, Pages 901-905

  Peron, Julien ^a,b   Roy, Pascal ^a,b   Ozenne, Brice ^a,b   Roche, Laurent ^a,b   Buyse, Marc ^c,d  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HARVARD UNIVERSITY   (United States)

^d HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER SIMULATION; HUMAN; KAPLAN MEIER METHOD; NEOPLASMS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

COMPUTER SIMULATION; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85010672557     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.6359     Document Type: Article

References (31)

1. Hattori S, Henmi M. Estimation of treatment effects based on ossiblymiss ecified Cox regression. Lifetime Data Anal. 2012;18(4):408-433.
2. Schoenfeld DA. Sam le-size formula for the ro ortional-hazards regression model. Biometrics. 1983;39(2):499-503.
3. BobbioM, Demichelis B, Giustetto G. Com leteness of re orting trial results. Lancet. 1994;343(8907):1209-1211.
4. Royston P, Parmar MKB. Restricted mean survival time. BMC Med ResMethodol. 2013;13:152.
5. Klein JP, Logan B, HarhoffM, Andersen PK. Analyzing survival curves at a fixed oint in time. Stat Med. 2007;26(24):4505-4519.
6. Royston P, Parmar MKB. An a roach to trial design and analysis in the era of non- ro ortional hazards of the treatment effect. Trials. 2014;15:314.
7. Zhao L, Tian L, Uno H, et al. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a com arative clinical study. Clin Trials. 2012;9(5):570-577.
8. Logan BR, Klein JP, ZhangMJ. Com aring treatments in the resence of crossing survival curves: an a lication to bone marrow trans lantation. Biometrics. 2008;64(3):733-740.
9. Royston P, Parmar MKB, Altman DG. Visualizing length of survival in time-to-event studies. J Natl Cancer Inst. 2008;100(2):92-97.
10. Seruga B, Pond GR, Hertz PC, Amir E, Ocana A, Tannock IF. Com arison of absolute benefits of anticancer thera ies determined by sna shot and area methods. Ann Oncol. 2012;23(11):2977-2982.
11. CooryM, Lamb KE, SorichM. Risk-difference curves can be used to communicate time-de endent effects of adjuvant thera ies for early stage cancer. J Clin E idemiol. 2014;67(9): 966-972.
12. Buyse M. Generalized airwise com arisons of rioritized outcomes in the two-sam le roblem. Stat Med. 2010;29(30):3245-3257.
13. Buyse M. Reformulating the hazard ratio to enhance communication with clinical investigators. Clin Trials. 2008;5(6):641-642.
14. Johnston S, Pi en J Jr, Pivot X, et al. La atinib combined with letrozole versus letrozole and lacebo as first-line thera y for ostmeno ausal hormone rece tor- ositivemetastatic breast cancer. J Clin Oncol. 2009;27(33):5538-5546.
15. MaioM, Grob J-J, Aamdal S, et al. Five-year survival rates for treatment-naive atients with advanced melanoma who received i ilimumab lus dacarbazine in a hase III trial. J Clin Oncol. 2015;33 (10):1191-1196.
16. Oliansky DM, Rizzo JD, A lan PD, et al. The role of cytotoxic thera y with hemato oietic stem cell trans lantation in the thera y of acutemyeloid leukemia in children: an evidence-based review. Biol Blood Marrow Trans lant. 2007;13(1):1-25.
17. Mok TS,Wu YL, Thong rasert S, et al. Gefitinib or carbo latin- aclitaxel in ulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
18. Acion L, Peterson JJ, Tem le S, Arndt S. Probabilistic index. Stat Med. 2006;25(4):591-602.
19. Moser BK, McCann MH. Reformulating the hazard ratio to enhance communication with clinical investigators. Clin Trials. 2008;5(3):248-252.
20. Senn S. Probabilistic index: an intuitive non- arametric a roach to measuring the size of treatment effects by L. Acion, J. J. Peterson, S. Tem le and S. Arndt, Statistics in Medicine 2006; 25(4):591-602. Stat Med. 2006;25(22):3944-3946.
21. Acion L, Peterson JJ, Tem le S, Arndt S. Authors' re ly. Stat Med. 2006;25(22):3946-3948. doi:10.1002/sim.2586.
22. Tan LB, Mur hy R. Shifts in mortality curves. Lancet. 1999;354(9187):1378-1381.
23. Uno H, Claggett B, Tian L, et al.Moving beyond the hazard ratio in quantifying the between-grou difference in survival analysis. J Clin Oncol. 2014;32 (22):2380-2385.
24. Datta S. Estimating the mean life time using right censored data. Stat Methodol. 2005;2(1):65-69. doi:10.1016/j.stamet.2004.11.003.
25. Ajani JA. The area between the curves gets no res ect. J Clin Oncol. 2007;25(34):5531.
26. Edgington ES, Onghena P. Randomization Tests. 4th ed. New York, NY: Cha man Hall/CRC Press; 2007.
27. Good P. Com aring two o ulations. In: Good P. Resam ling Methods: A Practical Guide to Data Analysis. 3rd ed. New York, NY: Birkhauser; 2006:31-57.
28. Dmitrienko A, Tamhane AC, Bretz F. Multi le Testing Problems in Pharmaceutical Statistics. New York, NY: Cha man and Hall/CRC Press; 2009.
29. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70 (3):659-663. doi:10.1093/biomet/70.3.659.
30. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the e idermal growth factor rece tor underlying res onsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21): 2129-2139.
31. Bellera CA, MacGrogan G, Debled M, de Lara CT, Brouste V, Mathoulin-Pelissier S. Variables with time-varying effects and the Cox model. BMC Med ResMethodol. 2010;16:10-20.